Last reviewed · How we verify

Interferon-β [IFN-β] — Competitive Intelligence Brief

Interferon-β [IFN-β] (Interferon-β [IFN-β]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Immunology.

phase 2 Interferon Interferon receptor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Interferon-β [IFN-β] (Interferon-β [IFN-β]) — Sanofi. Interferon-β binds to the interferon receptor, activating a signaling cascade that modulates the immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Interferon-β [IFN-β] TARGET Interferon-β [IFN-β] Sanofi phase 2 Interferon Interferon receptor
Reiferon retard Reiferon retard MinaPharm Pharmaceuticals marketed Interferon alfa-2a (long-acting/sustained-release formulation) Type I interferon receptor (IFNAR)
Reiferon Retard in Arm 1 Reiferon Retard in Arm 1 MinaPharm Pharmaceuticals marketed Interferon alfa-2a (long-acting/sustained-release) Type I interferon receptor (IFNAR)
Rebif® (clone 484-39) Rebif® (clone 484-39) Merck KGaA, Darmstadt, Germany marketed Interferon beta-1a Type I interferon receptor (IFNAR)
Interferon Beta-1A Prefilled Syringe Interferon Beta-1A Prefilled Syringe Cinnagen phase 3 Interferon Type I interferon receptor (IFNAR)
Ypeginterferon alfa-2b Ypeginterferon alfa-2b Xiamen Amoytop Biotech Co., Ltd. phase 3 Interferon Interferon receptor
GC3107 GC3107 Green Cross Corporation phase 3 Interferon alpha fusion protein Type I interferon receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

  1. EMD Serono · 3 drugs in this class
  2. Cinnagen · 2 drugs in this class
  3. Tanabe Pharma Corporation · 2 drugs in this class
  4. Biogen · 1 drug in this class
  5. Celgene · 1 drug in this class
  6. EMD Serono Research & Development Institute, Inc. · 1 drug in this class
  7. Case Comprehensive Cancer Center · 1 drug in this class
  8. Hoffmann-La Roche · 1 drug in this class
  9. Human Genome Sciences Inc. · 1 drug in this class
  10. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Interferon-β [IFN-β] — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-ifn. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: